arrow_back Back to App

Pediatric Cancer Drug Supply Act: Ensuring Access to Critical Therapies.

This act aims to ensure the continuous availability of essential pediatric cancer drugs by establishing strategic reserves. This will provide peace of mind for parents and patients regarding treatment continuity, even during market shortages. The program is designed to protect the youngest patients from treatment interruptions that could have serious consequences.
Key points
Creating drug reserves: The Secretary of Health and Human Services will enter into agreements with manufacturers to maintain at least a 6-month reserve supply of key pediatric cancer drugs.
Essential drug list: A list of chemotherapeutic drugs deemed essential for treating pediatric cancer will be developed and regularly updated.
Preventing shortages: In case of a drug shortage, the Secretary can order manufacturers to distribute drugs from reserves to ensure treatment continuity.
Supporting domestic manufacturing: The program aims to encourage increased domestic drug manufacturing capacity and promote market competition.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_6963
Sponsor: Rep. Eshoo, Anna G. [D-CA-16]
Process start date: 2024-01-11
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pediatric Cancer Drug Supply Act of 2024

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_6963.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-01-11.

What are the main provisions?

Key points include:

  • Creating drug reserves: The Secretary of Health and Human Services will enter into agreements with manufacturers to maintain at least a 6-month reserve supply of key pediatric cancer drugs.
  • Essential drug list: A list of chemotherapeutic drugs deemed essential for treating pediatric cancer will be developed and regularly updated.
  • Preventing shortages: In case of a drug shortage, the Secretary can order manufacturers to distribute drugs from reserves to ensure treatment continuity.
  • Supporting domestic manufacturing: The program aims to encourage increased domestic drug manufacturing capacity and promote market competition.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Eshoo, Anna G. [D-CA-16].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health